← Back to Search

Nicotinic alpha-7 receptor agonist

1 for Schizophrenia (P50 Trial)

Phase 2
Waitlist Available
Led By Ann Olincy, MD, MPH
Research Sponsored by Memory Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose and day 1
Awards & highlights

P50 Trial Summary

The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio. Data produced in this study will provide useful information regarding the value of P50 as an efficacy biomarker, and provide evidence for the optimal dosing of MEM 3454 for additional P50 studies.

P50 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~all time points
This trial's timeline: 3 weeks for screening, Varies for treatment, and all time points for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the utility of P50 sensory gating as an efficacy biomarker for nicotinic alpha-7 agonist such as MEM 3454.
Secondary outcome measures
• Determine whether MMN correlates with P50.
• Investigate the safety and tolerability of MEM 3454 compared with placebo

P50 Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: 4Experimental Treatment1 Intervention
50 mg dose
Group II: 3Experimental Treatment1 Intervention
15 mg dose
Group III: 2Experimental Treatment1 Intervention
5 mg dose
Group IV: 1Experimental Treatment1 Intervention
1 mg dose
Group V: 5Placebo Group1 Intervention
Placebo dose

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheIndustry Sponsor
2,431 Previous Clinical Trials
1,090,056 Total Patients Enrolled
18 Trials studying Schizophrenia
8,020 Patients Enrolled for Schizophrenia
Memory PharmaceuticalsLead Sponsor
4 Previous Clinical Trials
483 Total Patients Enrolled
1 Trials studying Schizophrenia
160 Patients Enrolled for Schizophrenia
Ann Olincy, MD, MPHPrincipal InvestigatorUniversity of Colorado, Denver

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Archives of General PsychiatryJournal
Proof-of-concept Trial of an Α7 Nicotinic Agonist in Schizophrenia
Olincy, Ann, Josette G. Harris, Lynn L. Johnson, Vicki Pender, Susan Kongs, Diana Allensworth, Jamey Ellis, et al.. 2006. “Proof-of-concept Trial of an Α7 Nicotinic Agonist in Schizophrenia”. Archives of General Psychiatry. American Medical Association (AMA). doi:10.1001/archpsyc.63.6.630.
clinicaltrials.govStudy
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
2008. "A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00725855.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top